Company intelligence / Profile preview

Ensoma

Boston, Massachusetts, USAensoma.com ↗
Ownership
Private
Employees
~100
Development stage
Other
01

Overview

Ensoma develops one-time, off-the-shelf in vivo therapies that engineer hematopoietic stem cells directly within patients to create durable therapeutic effects. Their Engenious™ platform uses virus-like particles to deliver advanced gene editing tools including next-generation CRISPR technologies. The approach aims to simplify treatment logistics by avoiding ex vivo cell manipulation or myeloablative conditioning. They have demonstrated scalable manufacturing consistency and are advancing toward clinical trials with a focus on immuno-oncology and other applications.

Therapeutic areas
OncologyImmunologyHematology
Modalities
In vivo hematopoietic stem cell engineeringGene editing technologies including CRISPR-CasVirus-like particle (VLP)-based delivery systems
Industry
Biotech
02

Drug pipeline

2 assets

EN-374

2

1 more asset in the full pipeline.

03

Partnerships

Strategic collaboration with Takeda Pharmaceutical Company focused on research payments up to $100 million plus potential milestones related to their genomic medicine platform.

Beyond the preview

Go deeper on Ensoma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ensoma.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call